




Instance: composition-en-42901eb273bd1fa1c559a078fd30641d
InstanceOf: CompositionUvEpi
Title: "Composition for dectova Package Leaflet"
Description:  "Composition for dectova Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp31f85d65fa6d0a396f6352434353b5e7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - dectova"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Dectova is and what it is used for </li>
<li>What you need to know before you are given Dectova </li>
<li>How Dectova is given </li>
<li>Possible side effects </li>
<li>How to store Dectova </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What dectova is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What dectova is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dectova contains zanamivir, which belongs to a group of medicines called antivirals. 
Dectova is used to treat severe flu (influenza A or B virus infection). It is used when other flu treatments 
are not suitable. 
Adults and children aged 6 months or more can be treated with Dectova. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take dectova"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take dectova"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Dectova:<br />
* if you are allergic to zanamivir or any of the other ingredients of this medicine (listed in section 6). </p>
<p>Warnings and precautions </p>
<p>Serious skin or allergic reactions </p>
<p>Serious skin or allergic reactions may occur after Dectova is given. Symptoms may include skin or throat 
swelling, difficulty breathing, blistering rash or peeling skin (see also  Serious skin or allergic reactions  in 
section 4). </p>
<p>Sudden changes in behaviour, hallucinations and fits </p>
<p>During treatment with Dectova, changes in behaviour such as confusion and unresponsiveness may occur. 
Some people may also have hallucinations (seeing, hearing, or feeling things that are not there) or fits 
(seizures) which can lead to loss of consciousness. These symptoms also occur in people with flu who are 
not being given Dectova. So it is not known if Dectova played a part in causing them. </p>
<p>If you are immunocompromised (have a weakened immune system) </p>
<p>Your doctor may monitor you more closely if your immune system is not working properly to ensure the 
treatment is working. Your doctor may switch you to an alternative treatment where appropriate. </p>
<p>If you notice any of the above symptoms: 
  Tell a doctor or nurse immediately. </p>
<p>Other medicines and Dectova<br />
Tell your doctor if you are taking, have recently taken or might take any other medicines. </p>
<p>Pregnancy and breast-feeding<br />
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your 
doctor for advice before you are given this medicine. </p>
<p>Driving and using machines<br />
Dectova should not affect your ability to drive or use machines. </p>
<p>Dectova contains sodium 
This medicine contains 70.8 mg sodium (main component of cooking/table salt) in each vial. This is 
equivalent to 3.54% of the recommended maximum daily intake of sodium for an adult. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take dectova"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take dectova"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>How much Dectova is given<br />
Your doctor will decide how much Dectova is right for you. The amount you are given is based on your age, 
body weight, and the results of your blood tests (to check how well your kidneys are working). </p>
<p>Your dose may be increased or decreased depending on how well you respond to treatment. </p>
<p>Adults 
The recommended dose is 600 mg twice daily for 5 to 10 days. </p>
<p>If your kidneys are not working as well as they should, your doctor will decide on the reduced dose for you. </p>
<p>Children<br />
Your doctor will decide on the correct dose of Dectova. </p>
<p>When and how Dectova is given 
Dectova should be given as soon as possible, usually within 6 days of the symptoms of flu appearing. </p>
<p>A doctor or nurse will give you Dectova as an infusion (drip) into a vein. It is usually given into your arm 
over about 30 minutes. </p>
<p>If you have any questions on the use of Dectova, ask the doctor or nurse who is giving it you. </p>
<p>If you are given more Dectova than you should<br />
It is unlikely that you will be given too much, but if you think you have been given too much Dectova, tell 
your doctor or nurse immediately.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, Dectova can cause side effects, although not everybody gets them. 
Serious skin and allergic reactions may occur with Dectova, but there isn t enough information to 
estimate how likely they are. Contact your doctor or nurse straight away if you notice any of the following 
serious side effects: 
* very severe skin reactions such as: * a skin rash, which may blister, and looks like small targets (erythema multiforme) * a widespread rash with blisters and peeling skin, particularly occurring around the mouth, 
nose, eyes and genitals (Stevens-Johnson syndrome) * extensive peeling of the skin on much of the body surface (toxic epidermal necrolysis). 
* severe allergic reactions, including features such as itchy rash, swelling of the face, throat or tongue, 
breathing difficulty, light headedness and vomiting. </p>
<p>Common side effects 
These may affect up to 1 in 10 people 
  diarrhoea 
  liver damage (hepatocellular injury) 
  rash. </p>
<p>Common side effects that may show up in your blood tests: 
  increase in the level of liver enzymes (raised aminotransferases). </p>
<p>Uncommon side effects 
These may affect up to 1 in 100 people 
  itchy, bumpy rash (hives). </p>
<p>Uncommon side effects that may show up in your blood tests: 
  increase in the level of liver or bone enzymes (raised alkaline phosphatase). </p>
<p>Side effects where it is not known how likely they are to happen 
There isn t enough information to estimate how likely these side effects are: 
  acting strangely 
  seeing, hearing or feeling things which are not there 
  confused thinking 
  fits (seizures) 
  being less alert or not responding to loud sounds or being shaken </p>
<p>Reporting of side effects<br />
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in 
this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store dectova"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store dectova"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. </p>
<p>Vials of Dectova are for single use only. Any unused solution should be discarded. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Dectova contains 
The active substance is zanamivir. 
Each mL of Dectova contains 10 mg of zanamivir (as hydrate). Each vial contains 200 mg of zanamivir (as 
hydrate) in 20 mL. 
Other ingredients are sodium chloride and water for injections. </p>
<p>What Dectova looks like and contents of the pack 
Dectova is a clear, colourless solution for infusion. It is supplied in a 26 mL clear glass vial with a rubber 
stopper and an aluminium over-seal with a plastic flip off cap. </p>
<p>There is 1 vial in each pack. </p>
<p>Marketing Authorisation Holder 
GlaxoSmithKline Trading Services Limited 
12 Riverwalk 
Citywest Business Campus 
Dublin Ireland </p>
<p>Manufacturer 
GlaxoSmithKline Manufacturing S.P.A 
Strada Provinciale Asolana, 43056 San Polo di Torrile 
Parma 
Italy </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien<br />
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
T l/Tel: + 32 (0) 10 85 52 Lietuva<br />
GlaxoSmithKline Trading Services Limited<br />
Tel: +370 80000 <br />
GlaxoSmithKline Trading Services Limited<br />
Te .: +359 80018Luxembourg/Luxemburg<br />
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Belgique/Belgien 
T l/Tel: + 32 (0) 10 85 52  esk  republika<br />
GlaxoSmithKline, s.r.o. 
Tel: + 420 222 001 cz.info@gsk.com 
Magyarorsz g<br />
GlaxoSmithKline Trading Services Limited<br />
Tel.: +36 80088Danmark<br />
GlaxoSmithKline Pharma A/S 
Tlf: + 45 36 35 91 dk-info@gsk.com </p>
<p>Malta<br />
GlaxoSmithKline Trading Services Limited<br />
Tel: +356 80065Deutschland<br />
GlaxoSmithKline GmbH &amp; Co. KG 
Tel.: + 49 (0)89 36044 8produkt.info@gsk.com </p>
<p>Nederland<br />
GlaxoSmithKline BV 
Tel: + 31 (0)33 2081Eesti<br />
GlaxoSmithKline Trading Services Limited<br />
Tel: +372 8002Norge<br />
GlaxoSmithKline AS 
Tlf: + 47 22 70 20  <br />
GlaxoSmithKline   A.E.B.E. 
 : + 30 210 68 82  sterreich<br />
GlaxoSmithKline Pharma GmbH 
Tel: + 43 (0)1 97075 0 
at.info@gsk.com </p>
<p>Espa a<br />
GlaxoSmithKline, S.A. 
Tel: + 34 900 202 es-ci@gsk.com </p>
<p>Polska<br />
GSK Services Sp. z o.o. 
Tel.: + 48 (0)22 576 9France<br />
Laboratoire GlaxoSmithKline 
T l: + 33 (0)1 39 17 84 diam@gsk.com </p>
<p>Portugal<br />
GlaxoSmithKline   Produtos Farmac uticos, Lda. 
Tel: + 351 21 412 95 FI.PT@gsk.com 
Hrvatska 
GlaxoSmithKline Trading Services Limited<br />
Tel: +385 800787Rom nia<br />
GlaxoSmithKline Trading Services Limited<br />
Tel: +40 800672Ireland<br />
GlaxoSmithKline (Ireland) Limited 
Tel: + 353 (0)1 4955Slovenija<br />
GlaxoSmithKline Trading Services Limited 
Tel: +386 80688 sland<br />
Vistor hf. 
S mi:  +354 535 7Slovensk  republika<br />
GlaxoSmithKline Trading Services Limited 
Tel: +421 800500Italia<br />
GlaxoSmithKline S.p.A. 
Tel: + 39 (0)45 7741 Suomi/Finland<br />
GlaxoSmithKline Oy 
Puh/Tel: + 358 (0)10 30 30 <br />
GlaxoSmithKline Trading Services Limited<br />
 : +357 80070Sverige 
GlaxoSmithKline AB 
Tel: + 46 (0)8 638 93 info.produkt@gsk.com </p>
<p>Latvija 
GlaxoSmithKline Trading Services Limited<br />
Tel: +371 80205United Kingdom (Northern Ireland) 
GlaxoSmithKline Trading Services Limited 
Tel: + 44 (0)800 221customercontactuk@gsk.com </p>
<p>This leaflet was last revised in {month YYYY}.  </p>
<p>This medicine has been authorised under  exceptional circumstances . 
This means that for scientific reasons it has not been possible to get complete information on this medicine. 
The European Medicines Agency will review any new information on this medicine every year and this 
leaflet will be updated as necessary. </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-42901eb273bd1fa1c559a078fd30641d
InstanceOf: CompositionUvEpi
Title: "Composition for dectova Package Leaflet"
Description:  "Composition for dectova Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp31f85d65fa6d0a396f6352434353b5e7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - dectova"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du får Dectova 
3. Sådan får du Dectova 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What dectova is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What dectova is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dectova indeholder zanamivir, som tilhører en gruppe lægemidler, der kaldes antivirale midler. 
Dectova bruges til at behandle alvorlig influenza (influenza A eller B virusinfektion). Det bruges, 
når andre influenzabehandlinger ikke er egnede. 
Voksne og børn i alderen 6 måneder og derover kan behandles med Dectova. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take dectova"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take dectova"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Få ikke Dectova:  </p>
<ul>
<li>hvis du er allergisk over for zanamivir eller et af de øvrige indholdsstoffer i Dectova (angivet i 
punkt 6). </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Alvorlige hudreaktioner eller allergiske reaktioner </p>
<p>Der kan forekomme alvorlige hudreaktioner og allergiske reaktioner, efter at du har fået Dectova. 
Symptomer kan omfatte hævelse af huden eller i halsen, vejrtrækningsbesvær, udslæt med blærer eller 
afskallende hud (se også "Alvorlige hudreaktioner eller allergiske reaktioner’ i punkt 4). </p>
<p>Pludselige ændringer i adfærd, hallucinationer og anfald </p>
<p>Under behandling med Dectova kan der forekomme ændringer i adfærd såsom forvirring og passivitet. 
Nogle mennesker kan også få hallucinationer (se, høre eller føle ting, som ikke er der) eller 
krampeanfald, som kan føre til, at de mister bevidstheden. Disse symptomer forekommer også hos 
mennesker med influenza, som ikke fik Dectova. Så derfor vides det ikke, om Dectova var med til at 
fremkalde symptomerne. </p>
<p>Hvis du er immunsvækket (har et nedsat immunforsvar). </p>
<p>Hvis dit immunforsvar ikke virker optimalt, kan din læge vælge at følge dig nøjere, for at sikre at 
behandlingen virker. Lægen kan om nødvendigt udskifte din behandling med en anden. </p>
<p>Hvis du bemærker nogen af de ovenfornævnte symptomer: 
 Fortæl det omgående til lægen eller sygeplejersken. </p>
<p>Brug af andre lægemidler sammen med Dectova<br />
Fortæl det altid til lægen hvis du tager andre lægemidler, for nylig har taget andre lægemidler eller 
planlægger at tage andre lægemidler. </p>
<p>Graviditet og amning<br />
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du får dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed<br />
Dectova bør ikke påvirke din evne til at føre motorkøretøj eller betjene maskiner.  </p>
<p>Dectova indeholder natrium 
Dette lægemiddel indeholder 70,8 mg natrium (hovedkomponent af madlavnings-/bordsalt) pr. 
hætteglas. Dette svarer til 3,54 % af den anbefalede maksimale daglige indtagelse af natrium for en 
voksen. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take dectova"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take dectova"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvor meget Dectova får du<br />
Lægen afgør, hvor meget Dectova du skal have. Den mængde, du får, er baseret på din alder, 
legemsvægt og resultatet af dine blodprøver (for at tjekke, hvor godt dine nyrer fungerer).  </p>
<p>Din dosis kan blive sat op eller ned, afhængigt af hvor godt du reagerer på behandlingen. </p>
<p>Voksne 
Den anbefalede dosis er 600 mg to gange dagligt i 5 til 10 dage. </p>
<p>Hvis dine nyrer ikke fungerer så godt, som de burde, vil lægen fastsætte en nedsat dosis til dig. </p>
<p>Børn<br />
Lægen bestemmer den korrekte dosis Dectova. </p>
<p>Hvornår og hvordan bliver Dectova givet 
Dectova bør gives så hurtigt som muligt, normalt indenfor 6 dage efter at symptomer på influenza 
opstår. </p>
<p>En læge eller sygeplejerske giver dig Dectova som infusion i en blodåre (et drop). Det gives normalt i 
armen over ca. 30 minutter. </p>
<p>Spørg lægen eller sygeplejersken, som giver dig Dectova, hvis der er noget, du er i tvivl om. </p>
<p>Hvis du får for meget Dectova<br />
Det er ikke sandsynligt, at du får for meget, men hvis du mener, at du har fået for meget Dectova, skal 
du straks fortælle det til lægen eller sygeplejersken.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dectova kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Alvorlige hudreaktioner og allergiske reaktioner kan muligvis forekomme ved brug af Dectova, 
men der er ikke oplysninger nok til at vurdere, hvor sandsynlige de er. Kontakt din læge eller 
sygeplejerske med det samme hvis du oplever følgende bivirkninger: </p>
<ul>
<li>
<p>meget svære hudreaktioner såsom:  * hududslæt, der kan danne blærer, som ligner små målskiver (erythema multiforme) * udbredt udslæt med blærer og afskallende hud, der især forekommer omkring munden, 
næsen, øjnene og kønsorganerne (Stevens-Johnsons syndrom) * omfattende afskalning af huden på meget af kroppens overflade (toksisk epidermal 
nekrolyse). </p>
</li>
<li>
<p>alvorlige allergiske reaktioner, herunder kløende udslæt, hævelse af ansigt, hals eller tunge, 
vejrtrækningsbesvær, svimmelhed og opkastning. </p>
</li>
</ul>
<p>Almindelige bivirkninger 
Kan forekomme hos op til 1 ud af 10 personer </p>
<ul>
<li>
<p>diarré </p>
</li>
<li>
<p>leverskade (hepatocellulær skade) </p>
</li>
<li>
<p>udslæt. </p>
</li>
</ul>
<p>Almindelige bivirkninger, der muligvis kan ses i dine blodprøver: </p>
<ul>
<li>øget niveau af leverenzymer (øgede aminotransferaser). </li>
</ul>
<p>Ikke almindelige bivirkninger 
Kan forekomme hos op til 1 ud af 100 personer </p>
<ul>
<li>kløende, bulet udslæt (nældefeber). </li>
</ul>
<p>Ikke almindelige bivirkninger, der muligvis kan ses i dine blodprøver: </p>
<ul>
<li>øget niveau af lever- eller knogleenzymer (øget alkalisk phosphatase). </li>
</ul>
<p>Bivirkninger, hvor det ikke vides, hvor sandsynlige de er 
Der er ikke tilstrækkelig information til at fastslå hyppigheden af disse bivirkninger: 
• underlig adfærd 
• se, høre eller føle ting der ikke er der 
• uklare tanker 
• krampeanfald 
• at være mindre opmærksom eller ikke respondere på høje lyde eller på at blive rystet. </p>
<p>Indberetning af bivirkninger<br />
Hvis du oplever bivirkninger, bør du tale med din læge eller sygeplejerske. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks 
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store dectova"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store dectova"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og hætteglasset efter EXP. </p>
<p>Hætteglas med Dectova er kun til engangsbrug. Eventuel ubrugt opløsning bør bortskaffes. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dectova indeholder: 
Aktivt stof: zanamivir 
Hver ml Dectova indeholder 10 mg zanamivir (som hydrat). Hvert hætteglas indeholder 200 mg 
zanamivir (som hydrat) i 20 ml. 
Øvrige indholdsstoffer: natriumchlorid og vand til injektionsvæsker. </p>
<p>Udseende og pakningsstørrelser 
Dectova er en klar, farveløs opløsning til infusion. Det leveres i et 26 ml klart hætteglas med 
gummiprop og ekstra forsegling af aluminium med et fliplåg af plastik. </p>
<p>Der er 1 hætteglas i hver pakning. </p>
<p>Indehaver af markedsføringstilladelsen 
GlaxoSmithKline Trading Services Limited 
12 Riverwalk 
Citywest Business Campus 
Dublin Irland </p>
<p>Fremstiller 
GlaxoSmithKline Manufacturing S.P.A 
Strada Provinciale Asolana, 43056 San Polo di Torrile 
Parma 
Italien </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien<br />
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Tél/Tel: + 32 (0) 10 85 52<br />
Lietuva<br />
GlaxoSmithKline Trading Services Limited<br />
Tel: +370 80000България<br />
GlaxoSmithKline Trading Services Limited<br />
Teл.: +359 80018 
Luxembourg/Luxemburg<br />
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Belgique/Belgien 
Tél/Tel: + 32 (0) 10 85 52<br />
Česká republika<br />
GlaxoSmithKline, s.r.o. 
Tel: + 420 222 001 cz.info@gsk.com 
Magyarország<br />
GlaxoSmithKline Trading Services Limited<br />
Tel.: +36 80088 
Danmark<br />
GlaxoSmithKline Pharma A/S 
Tlf: + 45 36 35 91 dk-info@gsk.com </p>
<p>Malta<br />
GlaxoSmithKline Trading Services Limited<br />
Tel: +356 80065Deutschland<br />
GlaxoSmithKline GmbH &amp; Co. KG 
Tel.: + 49 (0)89 36044 8produkt.info@gsk.com 
Nederland<br />
GlaxoSmithKline BV 
Tel: + 31 (0)33 2081 </p>
<p>Eesti<br />
GlaxoSmithKline Trading Services Limited<br />
Tel: +372 8002 
Norge<br />
GlaxoSmithKline AS 
Tlf: + 47 22 70 20<br />
Ελλάδα<br />
GlaxoSmithKline Μονοπρόσωπη A.E.B.E. 
Τηλ: + 30 210 68 82<br />
Österreich<br />
GlaxoSmithKline Pharma GmbH 
Tel: + 43 (0)1 97075 0 
at.info@gsk.com </p>
<p>España<br />
GlaxoSmithKline, S.A. 
Tel: + 34 900 202 es-ci@gsk.com </p>
<p>Polska<br />
GSK Services Sp. z o.o. 
Tel.: + 48 (0)22 576 9France<br />
Laboratoire GlaxoSmithKline 
Tél: + 33 (0)1 39 17 84 diam@gsk.com </p>
<p>Portugal<br />
GlaxoSmithKline - Produtos Farmacêuticos, Lda. 
Tel: + 351 21 412 95 FI.PT@gsk.com 
Hrvatska 
GlaxoSmithKline Trading Services Limited<br />
Tel: +385 800787 
România<br />
GlaxoSmithKline Trading Services Limited<br />
Tel: +40 800672Ireland<br />
GlaxoSmithKline (Ireland) Limited 
Tel: + 353 (0)1 4955 
Slovenija<br />
GlaxoSmithKline Trading Services Limited 
Tel: +386 80688 
Ísland<br />
Vistor hf. 
Sími: +354 535 7 
Slovenská republika<br />
GlaxoSmithKline Trading Services Limited 
Tel: +421 800500 
Italia<br />
GlaxoSmithKline S.p.A. 
Tel: + 39 (0)45 7741 Suomi/Finland<br />
GlaxoSmithKline Oy 
Puh/Tel: + 358 (0)10 30 30<br />
Κύπρος 
GlaxoSmithKline Trading Services Limited<br />
Τηλ: +357 80070 
Sverige 
GlaxoSmithKline AB 
Tel: + 46 (0)8 638 93 info.produkt@gsk.com </p>
<p>Latvija 
GlaxoSmithKline Trading Services Limited<br />
Tel: +371 80205 
United Kingdom (Northern Ireland) 
GlaxoSmithKline Trading Services Limited 
Tel: + 44 (0)800 221customercontactuk@gsk.com </p>
<p>Denne indlægsseddel blev senest ændret {måned ÅÅÅÅ}.  </p>
<p>Dette lægemiddel er godkendt under "særlige vilkår". 
Det betyder, at det af videnskabelige årsager ikke har været muligt at opnå fuldstændig dokumentation 
for lægemidlet. 
Det Europæiske Lægemiddelagentur vil hvert år vurdere nye oplysninger om lægemidlet, og denne 
indlægsseddel vil om nødvendigt blive ajourført. </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu.  </p>
<p>Nedenstående oplysninger er kun til sundhedspersoner: </p>
<ol>
<li>OPLYSNINGER TIL SUNDHEDSPERSONER </li>
</ol>
<p>Klargøring af Dectova  </p>
<ul>
<li>
<p>Volumen af Dectova og det samlede volumen til infusion afhænger af patientens alder, vægt og 
nyrefunktion (se pkt. 4.2 i produktresuméet). </p>
</li>
<li>
<p>Dosis kan infunderes som leveret eller fortyndes i natriumchlorid 9 mg/ml (0,9 %) 
injektionsvæske, opløsning til enhver koncentration, der er større end eller lig med 0,2 mg/ml. </p>
</li>
<li>
<p>Hvert hætteglas er kun til engangsbrug. Når forseglingen er brudt, skal den resterende mængde 
bortskaffes. </p>
</li>
</ul>
<p>Sådan klargøres infusionsvæsken til intravenøs administration:  </p>
<ul>
<li>
<p>Anvend aseptisk teknik under hele klargøringen af dosis. </p>
</li>
<li>
<p>Beregn den nødvendige dosis og volumen af Dectova. </p>
</li>
<li>
<p>Bestem det volumen af natriumchlorid 9 mg/ml (0,9 %) injektionsvæske, opløsning, der skal 
anvendes til infusionsvæsken. </p>
</li>
<li>
<p>Med en steril kanyle og sprøjte trækkes et volumen natriumchlorid 9 mg/ml (0,9 %) 
injektionsvæske, opløsning (svarende til volumen af Dectova) op fra infusionsposen og 
bortskaffes. </p>
</li>
<li>
<p>Infusionsposer kan indeholde et yderligere overskud af natriumchlorid 9 mg/ml (0,9 %) 
injektionsvæske, opløsning - dette kan også fjernes, hvis det anses for nødvendigt. </p>
</li>
<li>
<p>Med en steril kanyle og sprøjte trækkes volumen af Dectova op af hætteglasset/-glassene og 
tilføres infusionsposen. </p>
</li>
<li>
<p>Bortskaf en eventuel ikke anvendt del af hætteglasset. </p>
</li>
<li>
<p>Infusionsposen skal manipuleres forsigtigt med hånden for at sikre, at indholdet er blandet 
grundigt. </p>
</li>
<li>
<p>Hvis infusionsposen opbevares på køl, skal den tages ud af køleskabet og bringes op på 
stuetemperatur før brug. </p>
</li>
</ul>         </div>"""      





                    
Instance: bundlepackageleaflet-en-42901eb273bd1fa1c559a078fd30641d
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for dectova Package Leaflet for language en"
Description: "ePI document Bundle for dectova Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-42901eb273bd1fa1c559a078fd30641d"
* entry[0].resource = composition-en-42901eb273bd1fa1c559a078fd30641d

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp42901eb273bd1fa1c559a078fd30641d"
* entry[=].resource = mp42901eb273bd1fa1c559a078fd30641d
                            
                    
Instance: bundlepackageleaflet-da-42901eb273bd1fa1c559a078fd30641d
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for dectova Package Leaflet for language da"
Description: "ePI document Bundle for dectova Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-42901eb273bd1fa1c559a078fd30641d"
* entry[0].resource = composition-da-42901eb273bd1fa1c559a078fd30641d

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp42901eb273bd1fa1c559a078fd30641d"
* entry[=].resource = mp42901eb273bd1fa1c559a078fd30641d
                            
                    



Instance: mp42901eb273bd1fa1c559a078fd30641d
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Dectova 10 mg/mL solution for infusion"
Description: "Dectova 10 mg/mL solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/18/1349/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Dectova 10 mg/mL solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 42901eb273bd1fa1c559a078fd30641dListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "dectova"

* status = #current
* mode = #working

* title = "List of all ePIs associated with dectova"

* subject = Reference(mp31f85d65fa6d0a396f6352434353b5e7)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#dectova "dectova"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-42901eb273bd1fa1c559a078fd30641d) // dectova en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-42901eb273bd1fa1c559a078fd30641d) // dectova da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-42901eb273bd1fa1c559a078fd30641d
InstanceOf: List

* insert 42901eb273bd1fa1c559a078fd30641dListRuleset
    